Cyclophosphamide-Based In Vivo T-Cell Depletion for HLA-Haploidentical Transplantation in Fanconi Anemia

REFERENCES

• Kutler DI, Singh B, Satagopan J, A 20-year perspective on the international fanconi anemia registry (IFAR). Blood. 2003;101(4):1249–1256.
   PubMed Web of Science ®Google Scholar
• Wagner JE, Eapen M, MacMillan ML, Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood. 2007;109(5):2256–2262.
   PubMed Web of Science ®Google Scholar
• Thakar MS, Kurre P, Storb R, Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant. 2011;46(4):539–544.
   PubMed Web of Science ®Google Scholar
• Chaudhury S, Auerbach AD, Kernan NA, Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia (review). Br J Haematol. 2008;140(6):644–655.
   PubMed Web of Science ®Google Scholar
• Motwani J, Lawson SE, Darbyshire PJ. Successful HSCT using nonradiotherapy-based conditioning regimens and alternative donors in patients with Fanconi anaemia—experience in a single UK centre. Bone Marrow Transplant. 2005;36(5):405–410.
   PubMed Web of Science ®Google Scholar
• Rossi G, Giorgiani G, Comoli P, Successful T-cell-depleted, related haploidentical peripheral blood stem cell transplantation in a patient with Fanconi anaemia using a fludarabine-based preparative regimen without radiation. Bone Marrow Transplant. 2003;31(6):437–440.
   PubMed Web of Science ®Google Scholar
• O'Donnell PV, Luznik L, Jones RJ, Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377–386.
   PubMed Web of Science ®Google Scholar
• Luznik L, O'Donnell PV, Symons HJ, HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–650.
   PubMed Web of Science ®Google Scholar
• Luznik L, Bolanos-Meade J, Zahurak M, High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010;115(16):3224–3230.
   PubMed Web of Science ®Google Scholar
• McSweeney PA, Niederwieser D, Shizuru JA, Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390–3400.
   PubMed Web of Science ®Google Scholar
• Maris MB, Niederwieser D, Sandmaier BM, HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102(6):2021–2030.
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Luznik L, Bolanos-Meade J, Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008;42(8):523–527.
   PubMed Web of Science ®Google Scholar
• Bonfim CM, de Medeiros CR, Bitencourt MA, HLA-matched related donor hematopoietic cell transplantation in 43 patients with fanconi anemia conditioned with 60 mg/kg of cyclophosphamide. Biol Blood Marrow Transplant. 2007;13:1455–1460.
   PubMed Web of Science ®Google Scholar
• Zanis-Neto J, Flowers MED, Medeiros CR, Low-dose cyclophosphamide conditioning for haematopoietic cell transplantation from HLA-matched related donors in patients with Fanconi anemia. Br J Haematol. 2005;130:99–106.
   PubMed Web of Science ®Google Scholar
• Glucksberg H, Storb R, Fefer A, Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.
   PubMed Web of Science ®Google Scholar
• Sivgin S, Baldane S, Kaynar L, Pretransplant serum ferritin level may be a predictive marker for outcomes in patients having undergone allogeneic hematopoietic stem cell transplantation. Neoplasma. 2012;59(2):183–190.
   PubMed Web of Science ®Google Scholar
• Gluckman E, Auerbach AD, Horowitz MM, Bone marrow transplantation for Fanconi anemia. Blood. 1995;86(7):2856–2862.
   PubMed Web of Science ®Google Scholar
• Guardiola P, Pasquini R, Dokal I, Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European group for blood and marrow transplantation. Blood. 2000;95(2):422–429.
   PubMed Web of Science ®Google Scholar
• MacMillan ML, Wagner JE. Haematopoeitic cell transplantation for Fanconi anaemia—when and how? (review). Br J Haematol. 2010;149(1):14–21.
   PubMed Web of Science ®Google Scholar
• Guardiola P, Socie G, Li X, Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome. Blood. 2004;103(1):73–77.
   PubMed Web of Science ®Google Scholar
• Masserot C, Peffault de Latour R, Rocha V, Head and neck squamous cell carcinoma in 13 patients with Fanconi anemia after hematopoietic stem cell transplantation. Cancer. 2008;113(12):3315–3322.
   PubMed Web of Science ®Google Scholar
• Boulad F, Gillio A, Small TN, Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts. Br J Haematol. 2000;111(4):1153–1157.
   PubMed Web of Science ®Google Scholar
• Dufort G, Pisano S, Incoronato A, Feasibility and outcome of haploidentical SCT in pediatric high-risk hematologic malignancies and Fanconi anemia in Uruguay. Bone Marrow Transplant. 2012;47(5):663–668.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Zecca M, Pession A, The outcome of children with Fanconi anemia given hematopoietic stem cell transplantation and the influence of fludarabine in the conditioning regimen: a report from the Italian pediatric group. Haematologica. 2007;92(10):1381–1388.
   PubMed Web of Science ®Google Scholar
• Luznik L, Jalla S, Engstrom LW, Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98(12):3456–3464.
   PubMed Web of Science ®Google Scholar
• Santos GW, Tutschka PJ, Brookmeyer R, Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant. 1987;1:21–28.
   Google Scholar
• MacMillan ML, Auerbach AD, Davies SM, Haematopoietic cell transplantation in patients with Fanconi anaemia using alternate donors: results of a total body irradiation dose escalation trial. Br J Haematol. 2000;109(1):121–129.
   PubMed Web of Science ®Google Scholar
• Yabe H, Inoue H, Matsumoto M, Allogeneic haematopoietic cell transplantation from alternative donors with a conditioning regimen of low-dose irradiation, fludarabine and cyclophosphamide in Fanconi anaemia. Br J Haematol. 2006;134(2):208–212.
   PubMed Web of Science ®Google Scholar
• MacMillan ML, Auerbach AD, Wagner JE. Hematopoietic cell transplantation in Fanconi anemia patients with biallelic BRCA2 mutations. Blood. 2004;104(11):776a, #2838 (abstract).
   Google Scholar